本文選題：眼眶淋巴瘤 + P-gp��； 參考：《天津醫(yī)科大學(xué)》2011年碩士論文

【摘要】：研究目的 制作眼眶淋巴瘤組織芯片；利用免疫組織化學(xué)檢測(cè)三種耐藥蛋白在眼眶淋巴瘤中的表達(dá)情況,初步探索該病的復(fù)發(fā)及預(yù)后不良機(jī)制 研究方法 1收集2003年至2008年期間診斷為眼眶淋巴瘤及反應(yīng)性淋巴增生患者的臨床病理資料,并對(duì)病人進(jìn)行隨訪。 2制作眼眶淋巴瘤組織芯片。 3應(yīng)用免疫組織化學(xué)檢測(cè)P-gp、GST-π、LRP在眼眶淋巴瘤中的表達(dá)。 4應(yīng)用SPSS13.0統(tǒng)計(jì)學(xué)軟件對(duì)數(shù)據(jù)進(jìn)行分析,以α=0.05為檢驗(yàn)水準(zhǔn),P0.05認(rèn)為有統(tǒng)計(jì)學(xué)意義。 研究結(jié)果 1 50例眼眶淋巴瘤和17例眼眶反應(yīng)性淋巴增生組織芯片經(jīng)HE染色后,病理診斷結(jié)果與原取材的大組織診斷完全一致；有4例眼眶淋巴瘤在免疫組織化學(xué)的染色過程中一脫片,因此末對(duì)這4例標(biāo)本的染色結(jié)果進(jìn)行統(tǒng)計(jì)。 2三種耐藥蛋白,P-gp和GST-π在眼眶淋巴瘤和反應(yīng)性淋巴增生組織芯片中有不同程度表達(dá),LRP在兩種組織中均為陰性表達(dá)。P-gp蛋白主要表達(dá)于細(xì)胞膜,在兩種病變的陽性表達(dá)率為87.0%和35.3%,其差異有統(tǒng)計(jì)學(xué)意義；GST-π表達(dá)于細(xì)胞漿,在兩種病變的陽性表達(dá)率為76.1%和41.2%,其差異有統(tǒng)計(jì)學(xué)意義。 3 46例淋巴瘤：P-gp和GST-π這兩種蛋白的陽性表達(dá)率在≥60歲和60歲年齡組間、男女性別組間、≥2.5cm和2.5cm腫瘤組間及≥1年和1年發(fā)病時(shí)間組間均無統(tǒng)計(jì)學(xué)意義。 4將有隨訪結(jié)果的35例眼眶淋巴瘤分為兩組,即預(yù)后不良組和預(yù)后良好組；P-gp在兩組間的表達(dá)率分別為85.7%和42.9%,其差異有統(tǒng)計(jì)學(xué)意義；GST-π在兩組間的表達(dá)率分別為78.7%和38.1%,其差異有統(tǒng)計(jì)學(xué)意義。 5 P-gp和GST-π在眼眶淋巴瘤中的表達(dá)呈正相關(guān)(P0.05)。 結(jié)論 1眼眶淋巴瘤組織芯片省時(shí)快速,結(jié)果可靠,高效經(jīng)濟(jì)地研究了該腫瘤的多藥耐藥基因表達(dá)狀況。 2 P-gp在眼眶淋巴瘤和反應(yīng)性淋巴增生組間陽性比率表達(dá)差異有統(tǒng)計(jì)學(xué)意義,說明P-gp對(duì)判斷眼眶淋巴細(xì)胞性疾病的病變性質(zhì)有一定價(jià)值；同時(shí)P-gp在眼眶淋巴瘤預(yù)后不良組和預(yù)后良好組間陽性率表達(dá)差異有統(tǒng)計(jì)學(xué)意義,說明P-gp可以預(yù)測(cè)眼眶淋巴瘤的預(yù)后。 3 GST-π在眼眶淋巴瘤和反應(yīng)性淋巴增生組間陽性率表達(dá)差異有統(tǒng)計(jì)學(xué)意義,說明P-gp對(duì)判斷眼眶淋巴細(xì)胞性疾病的病理性質(zhì)有一定意義；同時(shí)GST-π在眼眶淋巴瘤預(yù)后不良組和預(yù)后良好組間陽性率表達(dá)差異有統(tǒng)計(jì)學(xué)意義,說明GST-π可以預(yù)測(cè)眼眶淋巴瘤的預(yù)后 4 LRP在眼眶淋巴瘤和反應(yīng)性淋巴增生組均呈陰性表達(dá),提示LRP與眼眶淋巴細(xì)胞性疾病的發(fā)生發(fā)展無明確相關(guān)性。 5 P-gp和GST-π蛋白在眼眶淋巴瘤中的表達(dá)呈正相關(guān),聯(lián)合檢測(cè)這兩種指標(biāo)可能對(duì)預(yù)測(cè)眼眶淋巴瘤預(yù)后有更大價(jià)值。
[Abstract]:Research purpose The tissue microarray of orbital lymphoma was made and the expression of three kinds of drug-resistant proteins in orbital lymphoma was detected by immunohistochemistry to explore the recurrence of the disease and the mechanism of poor prognosis. Research method 1 clinicopathological data of patients with orbital lymphoma and reactive lymphoid hyperplasia from 2003 to 2008 were collected and followed up. 2 making tissue microarray of orbital lymphoma. 3Immunohistochemistry was used to detect the expression of P-gpt- 蟺 -LRP in orbital lymphoma. 4 SPSS13.0 statistical software was used to analyze the data, and the 偽 0. 05 test level was considered to be statistically significant (P0.05). Research results 150 cases of orbital lymphoma and 17 cases of orbital reactive lymphoid hyperplasia were stained by HE staining. Therefore, the staining results of these 4 specimens were statistically analyzed. 2the expression of P-gp and GST- 蟺 in orbital lymphoma and reactive lymphoproliferative tissue microarray was negative in both tissues. P-gp protein was mainly expressed on cell membrane. The positive expression rates of GST- 蟺 in the two lesions were 87.0% and 35.3.The difference was statistically significant. The positive expression rates of GST- 蟺 were 76.1% and 41.2% in the two lesions, respectively. The difference was statistically significant. 3The positive expression rates of P-gp and GST- 蟺 proteins in 46 cases of lymphoma were not significantly different between the age group 鈮，

本文編號(hào)：1943322